Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell ... MarketWatch (press release) Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell Transplant with or without REVLIMID Maintenance in Newly-Diagnosed Multiple Myeloma Presented at ASCO. MEL200 demonstrated a longer median PFS and OS compared ... ASCO 2013 Multiple Myeloma Update – Day Two: Education Session |
